+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), Age Group (Children, Adult, Elderly), Region, with Growth Forecasts, 2025-2030- Product Image
Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), Age Group (Children, Adult, Elderly), Region, with Growth Forecasts, 2025-2030- Product Image
New

Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), Age Group (Children, Adult, Elderly), Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 134 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 5950104
Description Jump to:
The Prediabetes Market was valued at USD 318.2 Million in 2024, and is projected to reach USD 585.7 Million by 2030, rising at a CAGR of 10.90%. Several factors drive the market growth. One of the main factors driving is the rising prevalence of prediabetes and increasing obesity rates. Obesity correlates with the development of diabetes. For instance, according to Washington University in St. Louis in June 2023, over 37 million individuals in the U.S. are affected by diabetes, with over 40% of them experiencing obesity, a condition associated with up to half of all diabetes cases. It is estimated that approximately 96 million Americans, constituting roughly one-third of adults, are living with prediabetes. Obesity, often linked with sedentary lifestyles and poor diet, is a significant risk factor for developing prediabetes. The rise in prediabetes cases has coincided with the global obesity epidemic, demonstrating the connection between these two health problems.

Moreover, genetic predisposition and family history also contribute significantly. While lifestyle factors play a predominant role, genetic factors can influence an individual's susceptibility to developing prediabetes, making specific populations more prone to the condition.

Prediabetes Market Report Highlights

  • Based on the drug class, the diguanide segment led the market with the largest revenue share of 78.8% in 2024. Metformin, a drug under the diguanide class is the first choice of drug for the treatment of prediabetes. It is the most commonly prescribed off-label drug for the treatment and slowing down the progression of prediabetes.
  • Based on the age group, the adult segment led the market with the largest revenue share in 2024. The increasing sedentary and disease-causing lifestyle among adults is the primary growth factor for this age group segment. The increasing prevalence of prediabetes along with increased awareness are driving the growth of this segment.
  • North America dominated the market with the revenue share of 41.3% in 2024, owing to the advanced healthcare infrastructure, high awareness, and high research activities for clinical trials. The region offers an advanced and strong research infrastructure. Community-based programs and support groups empower individuals with prediabetes to make sustainable lifestyle changes, such as healthy eating and regular physical activity.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Age Group
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Prediabetes Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Prediabetes Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Diguanide
4.4.1. Diguanide Market, 2018-2030 (USD Million)
4.5. Thiazolidinediones
4.5.1. Thiazolidinediones Market, 2018-2030 (USD Million)
4.6. Glucagon-like peptide-1 agonists (GLP-1)
4.6.1. Glucagon-like peptide-1 agonists (GLP-1) Market, 2018-2030 (USD Million)
4.7. SGLT2 inhibitors
4.7.1. SGLT2 inhibitors Market, 2018-2030 (USD Million)
4.8. DPP-4 inhibitors
4.8.1. DPP-4 inhibitors Market, 2018-2030 (USD Million)
4.9. Others
4.9.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Prediabetes Market: Age Group Business Analysis
5.1. Age Group Market Share, 2024 & 2030
5.2. Age Group Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2018 to 2030 (USD Million)
5.4. Children (12-18 years)
5.4.1. Children (12-18 years) Market, 2018-2030 (USD Million)
5.5. Adults (18-49)
5.5.1. Adults (18-49) Market, 2018-2030 (USD Million)
5.6. Elderly (50+)
5.6.1. Elderly (50+) Market, 2018-2030 (USD Million)
Chapter 6. Prediabetes Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
6.4. North America
6.4.1. North America Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamic
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamic
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamic
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamic
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamic
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamic
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamic
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamic
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamic
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Denmark Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamic
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Norway Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamic
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamic
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamic
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamic
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamic
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamic
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamic
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamic
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamic
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamic
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamic
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamic
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamic
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Prediabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Novo Nordisk a/S
7.5.1.1. Participant’s Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Valbiotis
7.5.2.1. Participant’s Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. RESVERLOGIX
7.5.3.1. Participant’s Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Caelus Health
7.5.4.1. Participant’s Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Scimar
7.5.5.1. Participant’s Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Boston Pharmaceuticals
7.5.6.1. Participant’s Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. APHAIA PHARMA AG
7.5.7.1. Participant’s Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. AstraZeneca
7.5.8.1. Participant’s Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Bristol-Myers Squibb Company
7.5.9.1. Participant’s overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Pfizer Inc.
7.5.10.1. Participant’s Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Prediabetes Market, by Region, 2018-2030 (USD Million)
Table 4 Global Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 5 Global Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 6 North America Prediabetes Market, by Country, 2018-2030 (USD Million)
Table 7 North America Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 8 North America Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 9 U.S. Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 10 U.S. Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 11 Canada Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 12 Canada Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 13 Mexico Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 14 Mexico Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 15 Europe Prediabetes Market, by Country, 2018-2030 (USD Million)
Table 16 Europe Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 17 Europe Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 18 U.K. Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 19 U.K. Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 20 Germany Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 21 Germany Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 22 France Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 23 France Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 24 Italy Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 25 Italy Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 26 Spain Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 27 Spain Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 28 Denmark Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 29 Denmark Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 30 Norway Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 31 Norway Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 32 Sweden Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 33 Sweden Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 34 Asia Pacific Prediabetes Market, by Country, 2018-2030 (USD Million)
Table 35 Asia Pacific Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 36 Asia Pacific Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 37 Japan Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 38 Japan Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 39 China Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 40 China Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 41 India Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 42 India Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 43 South Korea Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 44 South Korea Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 45 Australia Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 46 Australia Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 47 Thailand Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 48 Thailand Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 49 Latin America Prediabetes Market, by Country, 2018-2030 (USD Million)
Table 50 Latin America Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 51 Latin America Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 52 Brazil Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 53 Brazil Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 54 Argentina Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 55 Argentina Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 56 Middle East & Africa Prediabetes Market, by Country, 2018-2030 (USD Million)
Table 57 Middle East & Africa Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 58 Middle East & Africa Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 59 South Africa Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 60 South Africa Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 61 Saudi Arabia Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 62 Saudi Arabia Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 63 UAE Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 64 UAE Prediabetes Market, by Age Group, 2018-2030 (USD Million)
Table 65 Kuwait Prediabetes Market, by Drug Class, 2018-2030 (USD Million)
Table 66 Kuwait Prediabetes Market, by Age Group, 2018-2030 (USD Million)
List of Figures
Figure 1 Prediabetes Market Segmentation
Figure 2 Market Research Process
Figure 3 Data Triangulation Techniques
Figure 4 Primary Research Pattern
Figure 5 Market Research Approaches
Figure 6 Value-Chain-Based Sizing & Forecasting
Figure 7 Market Formulation & Validation
Figure 8 Market Snapshot
Figure 9 Drug Class and Age Group Outlook (USD Million)
Figure 10 Competitive Landscape
Figure 11 Prediabetes Market Dynamics
Figure 12 Prediabetes Market: Porter’s Five Forces Analysis
Figure 13 Prediabetes Market: PESTLE Analysis
Figure 14 Prediabetes Market: Drug Class Segment Dashboard
Figure 15 Prediabetes Market: Drug Class Market Share Analysis, 2024 & 2030
Figure 16 Diguanide Market, 2018-2030 (USD Million)
Figure 17 Thiazolidinediones Market, 2018-2030 (USD Million)
Figure 18 Glucagon-like peptide-1 agonists (GLP-1) Market, 2018-2030 (USD Million)
Figure 19 SGLT2 Inhibitors Market, 2018-2030 (USD Million)
Figure 20 DPP-4 Inhibitors Market, 2018-2030 (USD Million)
Figure 21 Others Market, 2018-2030 (USD Million)
Figure 22 Prediabetes Market: Age Group Segment Dashboard
Figure 23 Prediabetes Market: Age Group Market Share Analysis, 2024 & 2030
Figure 24 Children (12-18 years) Market, 2018-2030 (USD Million)
Figure 25 Adults (18-49) Market, 2018-2030 (USD Million)
Figure 26 Elderly (50+) Market, 2018-2030 (USD Million)
Figure 27 Prediabetes Market Revenue, By Region
Figure 28 Regional Marketplace: Key Takeaways
Figure 29 Regional Marketplace: Key Takeaways
Figure 30 North America Prediabetes Market, 2018-2030 (USD Million)
Figure 31 U.S. Country Dynamics
Figure 32 U.S. Prediabetes Market, 2018-2030 (USD Million)
Figure 33 Canada Country Dynamics
Figure 34 Canada Prediabetes Market, 2018-2030 (USD Million)
Figure 35 Mexico Country Dynamics
Figure 36 Mexico Prediabetes Market, 2018-2030 (USD Million)
Figure 37 Europe Prediabetes Market, 2018-2030 (USD Million)
Figure 38 UK Country Dynamics
Figure 39 UK Prediabetes Market, 2018-2030 (USD Million)
Figure 40 Germany Country Dynamics
Figure 41 Germany Prediabetes Market, 2018-2030 (USD Million)
Figure 42 France Country Dynamics
Figure 43 France Prediabetes Market, 2018-2030 (USD Million)
Figure 44 Italy Country Dynamics
Figure 45 Italy Prediabetes Market, 2018-2030 (USD Million)
Figure 46 Spain Country Dynamics
Figure 47 Spain Prediabetes Market, 2018-2030 (USD Million)
Figure 48 Denmark Country Dynamics
Figure 49 Denmark Prediabetes Market, 2018-2030 (USD Million)
Figure 50 Norway Country Dynamics
Figure 51 Norway Prediabetes Market, 2018-2030 (USD Million)
Figure 52 Sweden Country Dynamics
Figure 53 Sweden Prediabetes Market, 2018-2030 (USD Million)
Figure 54 Asia Pacific Prediabetes Market, 2018-2030 (USD Million)
Figure 55 Japan Country Dynamics
Figure 56 Japan Prediabetes Market, 2018-2030 (USD Million)
Figure 57 China Country Dynamics
Figure 58 China Prediabetes Market, 2018-2030 (USD Million)
Figure 59 India Country Dynamics
Figure 60 India Prediabetes Market, 2018-2030 (USD Million)
Figure 61 South Korea Country Dynamics
Figure 62 South Korea Prediabetes Market, 2018-2030 (USD Million)
Figure 63 Australia Country Dynamics
Figure 64 Australia Prediabetes Market, 2018-2030 (USD Million)
Figure 65 Thailand Country Dynamics
Figure 66 Thailand Prediabetes Market, 2018-2030 (USD Million)
Figure 67 Latin America Prediabetes Market, 2018-2030 (USD Million)
Figure 68 Brazil Country Dynamics
Figure 69 Brazil Prediabetes Market, 2018-2030 (USD Million)
Figure 70 Argentina Country Dynamics
Figure 71 Argentina Prediabetes Market, 2018-2030 (USD Million)
Figure 72 Middle East & Africa Prediabetes Market, 2018-2030 (USD Million)
Figure 73 South Africa Country Dynamics
Figure 74 South Africa Prediabetes Market, 2018-2030 (USD Million)
Figure 75 Saudi Arabia Country Dynamics
Figure 76 Saudi Arabia Prediabetes Market, 2018-2030 (USD Million)
Figure 77 UAE Country Dynamics
Figure 78 UAE Prediabetes Market, 2018-2030 (USD Million)
Figure 79 Kuwait Key Country Dynamics
Figure 80 Kuwait Prediabetes Market, 2018-2030 (USD Million)
Figure 81 Company Categorization
Figure 82 Company Market Position Analysis
Figure 83 Strategic Framework

Companies Mentioned

The companies profiled in this Prediabetes market report include:
  • Novo Nordisk A/S
  • Valbiotis
  • RESVERLOGIX
  • Caelus Health
  • Scimar
  • Boston Pharmaceuticals
  • APHAIA PHARMA AG
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages134
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 318.2 Million
Forecasted Market Value ( USD ) by 2030 $ 585.7 Million
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Prediabetes Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Prediabetes Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 184 Pages
  • Global
From
Prediabetes - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Prediabetes - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Pandemic of Diabetes and Prediabetes: Prevention and Control, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 50-3 - Product Image

Pandemic of Diabetes and Prediabetes: Prevention and Control, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 50-3

  • Book
  • North America
Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 47-1 - Product Image

Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 47-1

  • Book
  • North America
Next Generation Diabetes Therapy and Drug Delivery Market 2025-2033 - Product Image

Next Generation Diabetes Therapy and Drug Delivery Market 2025-2033

  • Report
  • 149 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.